Risk of Heart Failure in Breast Cancer Patients After Anthracycline and Trastuzumab Treatment: A Retrospective Cohort Study

2012556 citationsJournal Articlebronze Open Access

Authors

Erin J. Aiello Bowles · Group Health Cooperative

Robert Wellman · Group Health Cooperative

Heather Spencer Feigelson

Adedayo A. Onitilo

Andrew N. Freedman · National Institutes of Health

Thomas Delate

Larry A. Allen · University of Colorado Denver

Larissa Nekhlyudov · Harvard Vanguard Medical Associates

Abstract

Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased HF/CM risk compared with no chemotherapy. This population-based observational study complements findings from clinical trials on cancer treatment safety.

Topics & Keywords

Chemotherapy-induced cardiotoxicity and mitigation HER2/EGFR in Cancer Research Cancer Treatment and Pharmacology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JNCI Journal of the National Cancer Institute

Volume 104, Issue 17, pp. 1293-1305

DOI: 10.1093/jnci/djs317

Field-Weighted Citation Impact: 22.76